# A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

> **NCT02141997** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 222 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** adalimumab
- **BIOLOGICAL:** ABT-122

## Key facts

- **NCT ID:** NCT02141997
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-09
- **Final completion:** 2015-11
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2016-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141997, "A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02141997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*